CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 846 enrolled
Drug / intervention
Lasmiditan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03962738
NCT03962738Phase 2Completed
CompareCT.gov

RandoMized, DOuble-bliNd, PlacebO-coNtrolled Trial Of Lasmiditan in a Single Migraine Attack in Japanese Patients SuFfering From Migraine With or WithoUt Aura - the MONONOFU Study

Eli Lilly and Company·interventional·Posted May 24, 2019·Updated Jun 11, 2021

In Brief

A Phase 2 clinical trial evaluating Lasmiditan and Placebo for Migraine. Completed, enrolled 846 participants across 34 sites.

Detailed Summary

This study will assess the efficacy and safety of lasmiditan in the acute treatment of a migraine attack in Japanese adult participants with or without aura.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 24, 2019
Enrollment StartMay 31, 2019
Primary CompletionJun 8, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.1 years ago

Interventions

Lasmiditandrug

Administered orally

Placebodrug

Administered orally